Opioid Damages and Health Care Costs Recovery Act, 2019, S.O. 2019, c. 17, Sched. 2
Section 3
Recovery of cost of health care benefits on aggregate basis
Cite as Opioid Damages and Health Care Costs Recovery Act, 2019, S.O. 2019, c. 17, Sched. 2, s. 3 · current to November 11, 2026 · consolidated from June 6, 2024 · read from e-Laws on November 16, 2026
The text
(1) In an action under subsection 2 (1) or 2.1 (1) for the recovery of the cost of health care benefits on an aggregate basis, subsection (2) applies if the Crown in right of Ontario or the Crown in right of Canada, as the case may be, proves, on a balance of probabilities, that, in respect of a type of opioid product,
(a) the defendant breached a common law, equitable or statutory duty or obligation owed to insured persons who have used or been exposed to or might use or be exposed to the type of opioid product;
(b) using the type of opioid product can cause or contribute to disease, injury or illness; and
(c) during all or part of the period of the breach referred to in clause (a), the type of opioid product, manufactured or promoted by the defendant, was offered for distribution or sale in Ontario. 2019, c. 17, Sched. 2, s. 3 (1); 2023, c. 21, Sched. 9, s. 4.
(2) Subject to subsections (1) and (4), the court shall presume that,
(a) the population of insured persons who used or were exposed to the type of opioid product manufactured or promoted by the defendant would not have used or been exposed to the product but for the breach referred to in clause (1) (a); and
(b) the use or exposure described in clause (a) of this subsection caused or contributed to disease, injury or illness or the risk of disease, injury or illness in a portion of the population described in that clause. 2019, c. 17, Sched. 2, s. 3 (2).
(3) If the presumptions under clauses (2) (a) and (b) apply,
(a) the court shall determine on an aggregate basis the cost of health care benefits provided after the date of the breach referred to in clause (1) (a) resulting from use or exposure to the type of opioid product; and
(b) each defendant to which the presumptions apply is liable for the proportion of the aggregate cost referred to in clause (a) of this subsection equal to its market share in the type of opioid product. 2019, c. 17, Sched. 2, s. 3 (3).
(4) The amount of a defendant’s liability assessed under clause (3) (b) may be reduced, or the proportions of liability assessed under clause (3) (b) readjusted among the defendants, to the extent that a defendant proves, on a balance of probabilities, that the breach referred to in clause (1) (a) did not cause or contribute to the use or exposure referred to in clause (2) (a) or to the disease, injury or illness or risk of disease, injury or illness referred to in clause (2) (b). 2019, c. 17, Sched. 2, s. 3 (4).
Read the Opioid Damages and Health Care Costs Recovery Act, 2019 on e-Laws ↗